Core Viewpoint - Fosun Pharma (01652) has announced the conditional sale of its subsidiary, Henan Fosun Smart Energy Technology Co., Ltd., to Henan Xisheng Industrial Development Co., Ltd. for a total consideration of RMB 73 million, as part of a strategic move to streamline operations and focus on its core pharmaceutical business [1][2]. Group 1 - The group primarily engages in the manufacturing and sales of pharmaceuticals [2]. - The target company specializes in the installation and operation of photovoltaic power generation systems, aimed at supporting the group's internal power needs and generating external sales revenue [2]. - The photovoltaic business is not a core focus of the group, leading to the decision to sell this non-core subsidiary [2]. Group 2 - The sale is a strategic action intended to consolidate resources, enhance operational efficiency, and reallocate management and financial focus back to the core pharmaceutical business [2]. - By restructuring its business portfolio and exiting peripheral industries, the group aims to strengthen its competitive position and enhance its ability to seize new growth opportunities in the pharmaceutical sector [2]. - The net proceeds from the sale will provide immediate cash inflow, intended for general working capital, including operational expenses and support for the ongoing development of the core pharmaceutical business [2]. - The board believes the terms of the sale are fair and reasonable, aligning with the overall interests of the company and its shareholders [2].
福森药业(01652)附属拟7300万元出售河南福森智慧节能科技全部股权